Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | DRD4 | P21917 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | WDR5 | P61964 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8778541 | 0.93 | HRH3 (0.57) | DRD2DRD4LMNAMAPK1HTT | |
| SCHEMBL28540629 | 0.93 | HRH3 (0.57) | DRD2DRD4LMNAMAPK1HTT | |
| SCHEMBL2000837 | 0.90 | LMNA (0.59) | DRD2DRD4LMNAMAPK1HTT | |
| SCHEMBL9808215 | 0.86 | LMNA (0.67) | DRD2DRD4LMNAMAPK1HTT | |
| SCHEMBL1685432 | 0.84 | DRD2 (0.62) | DRD2DRD4LMNAMAPK1HTT | |
| SCHEMBL9774806 | 0.82 | DRD2 (0.60) | DRD2DRD4LMNAMAPK1HTT | |
| SCHEMBL535552 | 0.82 | WDR5 (0.55) | DRD2DRD4LMNAMAPK1HTT | |
| SCHEMBL366494 | 0.81 | LMNA (0.57) | DRD2DRD4LMNAMAPK1HTT | |
| SCHEMBL6846799 | 0.81 | DRD2 (0.58) | DRD2DRD4LMNAMAPK1HTT | |
| SCHEMBL5825855 | 0.81 | KMT2A (0.60) | DRD2DRD4LMNAMAPK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1252048-C | Process for the preparation of an enantiomerically enriched thio compound | DSM IP NV (NL) | 2006-04-19 | — | — | CN | disclosed |
| US-20050107468-A1 | Process for the preparation of an enantiomerically enriched thio compound | DSM IP ASSETS B.V. (NL) | 2005-05-19 | — | — | US | disclosed |
| CN-1602300-A | Process for preparing enantiomerically enriched thio compounds | DSM IP NV (NL) | 2005-03-30 | — | — | CN | disclosed |
| EP-1453797-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY ENRICHED THIO COMPOUND | DSM IP Assets B.V. (NL) | 2004-09-08 | — | — | EP | disclosed |
| EP-1325908-A1 | Process for the preparation of an enantiomerically enriched thio compound | DSM N.V. (NL) | 2003-07-09 | — | — | EP | disclosed |
| WO-2003051827-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY ENRICHED THIO COMPOUND | DSM IP ASSETS B.V. (NL) | 2003-06-26 | — | — | WO | disclosed |
| EP-0163895-B1 | PROCESS FOR THE DIASTEREOSELECTIVE REDUCTION OF ALPHA-TRIAZOLYL KETONES TO BETA-TRIAZOLYL CARBINOLS | BASF Aktiengesellschaft (DE) | 1989-04-12 | — | — | EP | disclosed |
| US-4748250-A | Diastereoselective reduction of alpha-triazolylketones to betatriazolylcarbinols | BASF AKTIENGESELLSCHAFT (DE) | 1988-05-31 | — | — | US | disclosed |
| US-4590291-A | Thrombin inhibitory new dihydroxybenzene ether derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1986-05-20 | — | — | US | disclosed |
| EP-0163895-A1 | Process for the diastereoselective reduction of alpha-triazolyl ketones to beta-triazolyl carbinols | BASF Aktiengesellschaft (DE) | 1985-12-11 | — | — | EP | disclosed |
| EP-0068250-A1 | Dioxybenzene ether derivatives, pharmaceutical compositions containing them, process for the preparation thereof and their use | BAYER AG (DE) | 1983-01-05 | — | — | EP | disclosed |
| US-4122282-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-10-24 | — | — | US | disclosed |
| US-4099014-A | BLOOD PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1978-07-04 | — | — | US | disclosed |
| US-4085139-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-04-18 | — | — | US | disclosed |
| US-4081478-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-03-28 | — | — | US | disclosed |
| US-4073808-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-02-14 | — | — | US | disclosed |
| US-4033989-A | 9-Deoxy-PGF2 Analogs | THE UPJOHN COMPANY (US) | 1977-07-05 | — | — | US | disclosed |
| US-4016184-A | PROSTAGLANDINS, BLOOD PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107468-A1 | Process for the preparation of an enantiomerically enriched thio compound | SLC7A1, TCP1, TFRC | DRD2 2609/4885DRD4 1726/4885LMNA 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.